Enrico Tiacci Selected Research

Nuclear Export Signals (Nuclear Export Signal)

12/2021	Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
1/2021	A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Enrico Tiacci Research Topics

Disease

12	Neoplasms (Cancer) 01/2022 - 01/2004
11	Hairy Cell Leukemia 01/2022 - 01/2004
11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2021 - 01/2005
5	Lymphoma (Lymphomas) 12/2020 - 01/2012
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2016 - 02/2004
2	Infections 01/2022 - 06/2021
2	Hodgkin Disease (Hodgkin's Disease) 01/2018 - 01/2010
2	Leukemia 05/2015 - 10/2004
1	Cytopenia 06/2021
1	Residual Neoplasm 06/2021
1	COVID-19 01/2021
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2020
1	Epstein-Barr Virus Infections 12/2020
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2020
1	Disease Progression 03/2017
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2016
1	Exanthema (Rash) 10/2015
1	Arthritis (Polyarthritis) 10/2015
1	Arthralgia (Joint Pain) 10/2015
1	Acute Promyelocytic Leukemia 05/2015
1	Melanoma (Melanoma, Malignant) 04/2013
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2011
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2006
1	Myeloid Leukemia (Leukemia, Myelocytic) 10/2004

Drug/Important Bio-Agent (IBA)

9	NucleophosminIBA 12/2021 - 01/2005
6	Biological ProductsIBA 01/2022 - 01/2004
5	purineIBA 01/2022 - 01/2012
3	Rituximab (Mabthera)FDA Link 01/2022 - 01/2021
3	VemurafenibIBA 06/2021 - 10/2015
3	Phosphotransferases (Kinase)IBA 01/2021 - 04/2015
3	Proteins (Proteins, Gene)FDA Link 05/2015 - 01/2005
3	Monoclonal AntibodiesIBA 11/2012 - 10/2004
2	Cladribine FDA LinkGeneric 01/2022 - 06/2021
2	Nuclear Export Signals (Nuclear Export Signal)IBA 12/2021 - 01/2021
1	Tryptophan (L-Tryptophan)FDA Link 12/2021
1	Protein CIBA 12/2021
1	dabrafenibIBA 11/2021
1	Purine NucleosidesIBA 06/2021
1	Pentostatin (Nipent)FDA LinkGeneric 06/2021
1	immunotoxin HA22IBA 06/2021
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021
1	Messenger RNA (mRNA)IBA 12/2020
1	Nucleic AcidsIBA 12/2020
1	MicroRNAs (MicroRNA)IBA 12/2020
1	Immunotoxins (Immunotoxin)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	Anaplastic Lymphoma KinaseIBA 01/2016
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2016
1	Protein Tyrosine PhosphatasesIBA 01/2016
1	Pharmaceutical PreparationsIBA 10/2015
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 05/2015
1	Arsenic Trioxide (Trisenox)FDA Link 05/2015
1	Oncogene Proteins (Oncogene Protein)IBA 05/2015
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 05/2015
1	Cyclin D1IBA 02/2014
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2013
1	RNA (Ribonucleic Acid)IBA 01/2013
1	Immunoglobulins (Immunoglobulin)IBA 11/2012
1	Co-Repressor ProteinsIBA 01/2012
1	NF-KappaB Inhibitor alphaIBA 01/2010
1	NF-kappa B (NF-kB)IBA 01/2010
1	ParaffinIBA 09/2006
1	Tyrosine (L-Tyrosine)FDA Link 01/2006
1	polyacrylamideIBA 04/2005
1	Annexin A6IBA 04/2005
1	PAX5 Transcription FactorIBA 10/2004
1	adhesion receptorIBA 01/2004
1	ChemokinesIBA 01/2004

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 01/2022 - 03/2017
2	Therapeutics 01/2021 - 01/2004
1	Aftercare (After-Treatment) 10/2015
1	Drug Tapering 10/2015
1	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 02/2004